These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 26739828)

  • 1. Impact of the Everolimus-eluting Bioresorbable Scaffold in Coronary Atherosclerosis.
    Campos CM; Garcia-Garcia HM; Muramatsu T; de Araujo Gonçalves P; Onuma Y; Dudek D; Thuesen L; Webster MW; Kitslaar P; Veldhof S; Reiber JH; Nieman K; Ormiston JA; Serruys PW
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):109-16. PubMed ID: 26739828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Five-year clinical and functional multislice computed tomography angiographic results after coronary implantation of the fully resorbable polymeric everolimus-eluting scaffold in patients with de novo coronary artery disease: the ABSORB cohort A trial.
    Onuma Y; Dudek D; Thuesen L; Webster M; Nieman K; Garcia-Garcia HM; Ormiston JA; Serruys PW
    JACC Cardiovasc Interv; 2013 Oct; 6(10):999-1009. PubMed ID: 24156961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vasomotor Function Comparative Assessment at 1 and 2 Years Following Implantation of the Absorb Everolimus-Eluting Bioresorbable Vascular Scaffold and the Xience V Everolimus-Eluting Metallic Stent in Porcine Coronary Arteries: Insights From In Vivo Angiography, Ex Vivo Assessment, and Gene Analysis at the Stented/Scaffolded Segments and the Proximal and Distal Edges.
    Gogas BD; Benham JJ; Hsu S; Sheehy A; Lefer DJ; Goodchild TT; Polhemus DJ; Bouchi YH; Hung OY; Yoo SY; Joshi U; Giddens DP; Veneziani A; Quyyumi A; Rapoza R; King SB; Samady H
    JACC Cardiovasc Interv; 2016 Apr; 9(7):728-41. PubMed ID: 27056313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial.
    Diletti R; Farooq V; Girasis C; Bourantas C; Onuma Y; Heo JH; Gogas BD; van Geuns RJ; Regar E; de Bruyne B; Dudek D; Thuesen L; Chevalier B; McClean D; Windecker S; Whitbourn RJ; Smits P; Koolen J; Meredith I; Li X; Miquel-Hebert K; Veldhof S; Garcia-Garcia HM; Ormiston JA; Serruys PW
    Heart; 2013 Jan; 99(2):98-105. PubMed ID: 23118346
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelial-dependent vasomotion in a coronary segment treated by ABSORB everolimus-eluting bioresorbable vascular scaffold system is related to plaque composition at the time of bioresorption of the polymer: indirect finding of vascular reparative therapy?
    Brugaletta S; Heo JH; Garcia-Garcia HM; Farooq V; van Geuns RJ; de Bruyne B; Dudek D; Smits PC; Koolen J; McClean D; Dorange C; Veldhof S; Rapoza R; Onuma Y; Bruining N; Ormiston JA; Serruys PW
    Eur Heart J; 2012 Jun; 33(11):1325-33. PubMed ID: 22507972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
    Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
    JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design.
    Diletti R; Serruys PW; Farooq V; Sudhir K; Dorange C; Miquel-Hebert K; Veldhof S; Rapoza R; Onuma Y; Garcia-Garcia HM; Chevalier B
    Am Heart J; 2012 Nov; 164(5):654-63. PubMed ID: 23137495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold: the ABSORB cohort B MSCT substudy.
    Onuma Y; Collet C; van Geuns RJ; de Bruyne B; Christiansen E; Koolen J; Smits P; Chevalier B; McClean D; Dudek D; Windecker S; Meredith I; Nieman K; Veldhof S; Ormiston J; Serruys PW;
    Eur Heart J Cardiovasc Imaging; 2017 May; 18(8):870-879. PubMed ID: 28329198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and imaging outcomes of acute scaffold disruption and late structural discontinuity after implantation of the absorb Everolimus-Eluting fully bioresorbable vascular scaffold: optical coherence tomography assessment in the ABSORB cohort B Trial (A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions).
    Onuma Y; Serruys PW; Muramatsu T; Nakatani S; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Garcia-Garcia HM; Veldhof S; Rapoza R; Ormiston JA
    JACC Cardiovasc Interv; 2014 Dec; 7(12):1400-11. PubMed ID: 25523532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable polylactide scaffold?
    Sotomi Y; Onuma Y; Suwannasom P; Tateishi H; Tenekecioglu E; Zeng Y; Cavalcante R; Jonker H; Dijkstra J; Foin N; Koon JN; Collet C; de Winter RJ; Wykrzykowska JJ; Stone GW; Popma JJ; Kozuma K; Tanabe K; Serruys PW; Kimura T
    EuroIntervention; 2016 Oct; 12(8):e998-e1008. PubMed ID: 27721215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Ormiston JA; de Bruyne B; Regar E; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Miquel-Hebert K; Rapoza R; García-García HM
    Circulation; 2010 Nov; 122(22):2301-12. PubMed ID: 21098436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: a virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial.
    Gogas BD; Serruys PW; Diletti R; Farooq V; Brugaletta S; Radu MD; Heo JH; Onuma Y; van Geuns RJ; Regar E; De Bruyne B; Chevalier B; Thuesen L; Smits PC; Dudek D; Koolen J; Windecker S; Whitbourn R; Miquel-Hebert K; Dorange C; Rapoza R; Garcia-Garcia HM; McClean D; Ormiston JA
    JACC Cardiovasc Interv; 2012 Jun; 5(6):656-65. PubMed ID: 22721662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasomotor Response to Nitroglycerine Over 5 Years Follow-Up After Everolimus-Eluting Bioresorbable Scaffold Implantation.
    Dudek D; Rzeszutko Ł; Onuma Y; Sotomi Y; Depukat R; Veldhof S; Ediebah D; Staehr P; Zasada W; Malinowski KP; Kaluza GL; Serruys PW
    JACC Cardiovasc Interv; 2017 Apr; 10(8):786-795. PubMed ID: 28427595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A next-generation bioresorbable coronary scaffold system: from bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results.
    Verheye S; Ormiston JA; Stewart J; Webster M; Sanidas E; Costa R; Costa JR; Chamie D; Abizaid AS; Pinto I; Morrison L; Toyloy S; Bhat V; Yan J; Abizaid A
    JACC Cardiovasc Interv; 2014 Jan; 7(1):89-99. PubMed ID: 24139932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis: 5-Year Follow-Up.
    Serruys PW; Ormiston J; van Geuns RJ; de Bruyne B; Dudek D; Christiansen E; Chevalier B; Smits P; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Wasungu L; Ediebah D; Veldhof S; Onuma Y
    J Am Coll Cardiol; 2016 Feb; 67(7):766-76. PubMed ID: 26892411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term invasive follow-up of the everolimus-eluting bioresorbable vascular scaffold: five-year results of multiple invasive imaging modalities.
    Simsek C; Karanasos A; Magro M; Garcia-Garcia HM; Onuma Y; Regar E; Boersma E; Serruys PW; van Geuns RJ
    EuroIntervention; 2016 Jan; 11(9):996-1003. PubMed ID: 25349042
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes.
    Serruys PW; Onuma Y; Dudek D; Smits PC; Koolen J; Chevalier B; de Bruyne B; Thuesen L; McClean D; van Geuns RJ; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Sudhir K; Garcia-Garcia HM; Ormiston JA
    J Am Coll Cardiol; 2011 Oct; 58(15):1578-88. PubMed ID: 21958884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of coronary atherosclerosis by multislice computed tomography.
    Papadopoulou SL; Neefjes LA; Garcia-Garcia HM; Flu WJ; Rossi A; Dharampal AS; Kitslaar PH; Mollet NR; Veldhof S; Nieman K; Stone GW; Serruys PW; Krestin GP; de Feyter PJ
    JACC Cardiovasc Imaging; 2012 Mar; 5(3 Suppl):S28-37. PubMed ID: 22421228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
    Ellis SG; Kereiakes DJ; Metzger DC; Caputo RP; Rizik DG; Teirstein PS; Litt MR; Kini A; Kabour A; Marx SO; Popma JJ; McGreevy R; Zhang Z; Simonton C; Stone GW;
    N Engl J Med; 2015 Nov; 373(20):1905-15. PubMed ID: 26457558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.